Table 1 Baseline characteristics of NVAF patients with/without LAT/SEC

CHA₂DS₂-VASc score

1(0-1)

1(0-1)

1(0-1)

0.657

Paroxysmal AF, n

322(66.9)

277(70.5)

45(51.1)

<0.001*

Age, years

56.81±8.88

56.55±9.23

57.97±7.01

0.315

Male, n

317(65.9)

262(66.7)

55(62.5)

0.456

Smoke, n

179(37.2)

154(39.2)

25(28.4)

0.059

Alcohol consumption, n

71(14.8)

58(14.8)

13(14.8)

0.997

BMI, kg/m²

25.19±3.03

25.20±3.03

25.18±3.05

0.951

SBP, mmHg

121.40±18.09

121.42±18.63

121.30±15.57

0.955

DBP, mmHg

80(73-88)

79(73-87)

83.5(76-90)

0.008*

HR, bpm

75(66-85)

74(66-84)

77(67-88.75)

0.181

Hypertension, n

153(31.8)

120(30.5)

33(37.5)

0.205

Diabetes, n

19(4.0)

19(4.8)

0(0)

0.035*

CHD, n

17(3.5)

9(2.3)

8(9.1)

0.002*

Stroke/TIA, n

5(1.0)

5(1.3)

0(0)

0.287

Heart failure, n

10(2.1)

6(1.5)

4(4.5)

0.073

Anticoagulants, n

153(31.8)

118(30.0)

35(39.8)

0.076

Antiplatelet agents, n

81(16.8)

63(16.0)

18(20.5)

0.316

Statins, n

100(20.8)

82(20.9)

18(20.5)

0.932

RFCA, n

102(21.2)

102(26.1)

0

-

LAAC, n

19(4.0)

19(4.9)

0

-

RBC, ×10¹²/L

4.68(4.38-5.01)

4.68±0.53

4.75±0.50

0.239

MCV, fl

93.60(90.60-96.50)

93.80(90.80-96.90)

92.55(89.80-94.75)

0.014*

MCH, pg

31.00(30.10-32.00)

31.20(30.10-32.10)

30.75(30.03-31.50)

0.025*

PLT, ×10⁹/L

193.82±56.70

194.93±57.40

189.32±54.19

0.410

WBC, ×10⁹/L

5.70(4.71-6.86)

5.65(4.70-6.74)

5.89(4.87-7.35)

0.195

ALP, U/L

71.00(58.50-84.00)

70(58-83)

78(63.25-93.75)

0.004*

γ-GT, U/L

23.00(16.00-37.00)

23(15-35.50)

27.50(18.00-40.75)

0.058

BUN, mmol/L

6.18(5.28-7.39)

6.13(5.23-7.26)

6.58(5.51-7.63)

0.104

Scr, umol/L

0.87(0.73-1.02)

62.91±16.80

59.80±18.60

0.124

TC, mmol/L

3.69(3.09-4.26)

3.70(3.16-4.29)

3.53(2.92-4.14)

0.115

TG, mmol/L

1.11(0.82-1.58)

1.12(0.82-1.60)

1.05(0.81-1.52)

0.552

HDL-C, mmol/L

0.97(0.85-1.14)

0.98(0.86-1.16)

0.94(0.81-1.07)

0.067

LDL-C, mmol/L

2.14(1.61-2.68)

2.22±0.78

2.15±0.85

0.467

ApoA, g/L

1.11(1.02-1.24)

1.12(1.02-1.25)

1.08(1.02-1.17)

0.052

ApoB, g/L

0.72±0.21

0.72±0.21

0.70±0.23

0.414

Lp(a), mg/L

164.00(91.50-266.00)

146.00(86.50-229.00)

281.50(178.25-394.75)

<0.001*

PT, s

12.70(11.30-14.10)

12.50(11.30-13.80)

13.45(11.63-15.60)

0.003*

APTT, s

30.60(26.80-36.70)

30.20(26.73-36.30)

34.10(27.45-39.20)

0.035*

FIB, g/L

2.63(2.29-3.04)

2.63(2.29-3.04)

2.61(2.24-2.99)

0.573

D-Dimer, mg/L

0.23(0.13-0.39)

0.24(0.13-0.39)

0.19(0.10-0.37)

0.219

NT-proBNP, pg/mL

348.3(102.50-770.70)

286.20(87.82-651.70)

703.90(302.80-1367.00)

<0.001*

LAD, mm

35.00(31.00-39.50)

34.0(31.0-39.0)

39.0(35.0-43.0)

<0.001*

IVSA, mm

8.00(7.00-9.00)

8.0(7.0-9.0)

8.0(7.0-9.0)

0.027*

MPAD, mm

22.00(20.00-24.00)

22.0(20.0-24.0)

23.0(21.0-24.0)

0.252

LVEF, %

66.00(62.00-70.00)

67.0(62.0-70.0)

65.0(60.25-69.0)

0.038*